FDA CDRH Introduces the Patient and Caregiver Connection Program: What It Means for Device Registration and Post-Market Compliance

Key Takeaways

• The U.S. Food and Drug Administration's Center for Devices and Radiological Health (CDRH) has published an introduction to its Patient and Caregiver Connection program, which is designed to systematically collect feedback from patients and caregivers on disease experience, device use experience and device-related trends, so that regulatory decisions are informed by real-world context.
• The program brings the patient perspective into medical device design, clinical evaluation, post-market safety monitoring and product improvement.
• Chinese medical device companies planning to enter the U.S. market should note FDA's emphasis on patient experience evidence and should assess in advance how it may affect registration strategy, technical documentation, clinical evaluation and post-market compliance.

Source and Applicability

Source: FDA CDRH News & Updates

Original publication date: August 6, 2026

AIMEILI publication date: August 12, 2026

Source link: https://www.fda.gov/about-fda/division-patient-centered-development/cdrh-patient-and-caregiver-connection

This article is compiled and translated from public information issued by FDA CDRH News & Updates. Specific requirements are subject to the latest official publications of the regulatory authority.

Full Translation: CDRH Patient and Caregiver Connection

The Patient and Caregiver Connection gives patients and caregivers the opportunity to share their experience of living with a disease or using a medical device with staff at FDA's Center for Devices and Radiological Health (CDRH). CDRH's mission is to protect and promote the public health.

What Is the Patient and Caregiver Connection?

The Patient and Caregiver Connection is a partnership mechanism that gives CDRH staff broad and timely access to the experiences of patients and caregivers. Partner organizations collect feedback from their members on specific questions and share that feedback with CDRH. Patient feedback can illustrate how a disease affects an individual patient and can provide rich context for regulatory decision-making.

Why Did CDRH Establish the Patient and Caregiver Connection?

Engaging with patients and caregivers through the Patient and Caregiver Connection strengthens CDRH's ability to listen to, understand and integrate their perspectives into its work.

CDRH wants to work with patients and caregivers to advance the development and evaluation of innovative medical devices and to monitor the performance of devices already on the market. The partnerships under the Patient and Caregiver Connection will help build a meaningful and sustained culture of patient engagement among CDRH staff, patients and caregivers.

How Does the Patient and Caregiver Connection Help CDRH?

CDRH established the Patient and Caregiver Connection to obtain three categories of patient feedback that provide context for its regulatory activities:

• The lived experience of patients with a specific disease;
• Patients' experience of using devices to diagnose, treat or manage their disease;
• Current issues or trends related to medical devices that patients have used or may receive as treatment.

This information may also provide valuable insights for medical device design, the clinical studies used to evaluate medical devices, post-market medical device safety monitoring and product improvement.

How Does the Patient and Caregiver Connection Work?

When CDRH staff recognize that patient input is important to their work, they can contact the Patient and Caregiver Connection. Staff can draft questions for patients, caregivers or both, and partner organizations distribute the questions or questionnaires to their members and collect responses. Partner organizations aggregate the responses and share them with CDRH, ensuring that no personally identifiable information is included. The feedback obtained provides CDRH staff with broader context and a deeper understanding of patient experience in the course of their work.

The program is intended to broaden CDRH staff access to patient perspectives; it does not provide policy advice, recommendations or opinions.

Who Are the Partner Organizations of the Patient and Caregiver Connection?

The partner organizations listed below cover multiple medical specialties and reflect a broad range of cross-cutting themes. CDRH expects to expand the areas covered by the Patient and Caregiver Connection and to include additional relevant partner organizations in the future, as resources allow.

• Sleep Apnea Patient Alliance (ASAP)
• American Association of Kidney Patients (AAKP)
• American Brain Coalition (ABC)
• Breakthrough T1D
• COPD Foundation
• Faces and Voices of Recovery (FAVOR)
• Facing Our Risk of Cancer Empowered (FORCE)
• Fight Colorectal Cancer
• Global Healthy Living Foundation (GHLF)
• International Children's Advisory Network (iCAN)
• Mended Hearts, Inc.
• The Michael J. Fox Foundation
• Muscular Dystrophy Association (MDA)
• National Alliance for Caregiving (NAC)
• National Alliance on Mental Illness (NAMI)
• National Leiomyosarcoma Foundation (NLMSF)
• National Organization for Rare Disorders (NORD)
• Neurotech Network
• North American Spinal Cord Injury Consortium (NASCIC)
• Obesity Action Coalition
• Sepsis Alliance
• Setting Scoliosis Straight (SSS)
• Spina Bifida Association (SBA)
• Susan G. Komen
• TMJ Association
• Health, Sleep and Circadian Network (WSCN)

AIMEILI Regulatory Interpretation and Business Impact

Information of this kind, published by FDA CDRH News & Updates, should first be incorporated by companies into their regulatory intelligence and post-market surveillance processes, rather than being read simply as general news. Companies need to determine whether the update concerns a guidance document, recall or safety matter, product approval, digital health, quality systems or post-market regulatory information, and to confirm whether it affects existing registration projects or products under development.

Where the content concerns specific products, test performance, risk communications or regulatory measures, companies should further assess whether it affects product classification, the 510(k), De Novo or PMA pathway, technical documentation, labeling and instructions for use, quality system records or post-market reporting obligations. Companies pursuing U.S. market registration should record the original link, publication date, scope of applicability and internal conclusions in the project file.

What Should Companies Review?

Companies should review the basis for product classification, the applicable regulatory provisions, predicate device or substantial equivalence determinations, performance testing, software and cybersecurity documentation, risk management, clinical evidence, labeling and instructions for use, and quality system readiness.

Common Risks

Common risks include misjudging the FDA pathway, overlooking changes in guidance documents, inadequately designed performance testing, overly broad labeling claims, unclear post-market reporting obligations, and applying documentation prepared for other markets directly to U.S. registration.

AIMEILI View

The systematic introduction of the Patient and Caregiver Connection by FDA CDRH appears to be a procedural statement, but it in fact sends an important signal: patient experience is gradually moving from a supporting reference into the formal context of U.S. medical device regulatory decision-making. For Chinese medical device companies, this requires early assessment and planning in at least four areas.

1. Registration Strategy

In the future, when submitting premarket applications to FDA, regulators may pay closer attention to whether a product addresses genuine patient pain points. Companies should map out as early as possible the disease burden of the target patient population, the limitations of existing treatments and the product's use scenarios, and incorporate this information into the registration strategy and the justification of intended use, rather than relying solely on physician opinion. Where competitors hold patient preference data, FDA may use it as a comparative benchmark during review; Chinese companies need to build their own evidence base in advance through patient interviews, questionnaires or published literature.

2. Technical Documentation and Clinical Evaluation

FDA has clearly stated that patient feedback is used in device design, clinical study design and post-market safety monitoring. When preparing a 510(k), De Novo or PMA, Chinese companies should consider introducing patient-reported outcomes, usability testing and patient preference studies as supplementary evidence for clinical evaluation. Particularly as FDA encourages patient-centered tools and outcome measures, laboratory performance data alone may not be sufficient to support demonstration of clinical benefit; companies need to assess whether additional patient-related data are required and to plan the corresponding timelines and budgets.

3. Labeling and Post-Market Maintenance

The program emphasizes collecting patient feedback on device use experience and current trends, which means FDA will also pay attention to real-world product performance after market launch. Chinese companies should establish proactive channels for collecting patient feedback, including complaint handling, adverse event reporting, and monitoring of social media and patient community information, and should incorporate this information into periodic risk assessments. In addition, the intended population, instructions for use, contraindications and risk warnings in labeling should be expressed in language patients can understand, in order to reduce real-world adverse events caused by misunderstanding of use.

4. Quality System and Local Agent Arrangements

Where companies operate through U.S. agents or distributors, they should ensure that relevant parties are aware of developments in CDRH's patient engagement programs and that communication with FDA is maintained as part of post-market surveillance. Although the program itself does not directly create new compliance obligations, FDA may consider during review and inspections whether a company has a systematic, patient-centered approach. Chinese companies are advised to reflect analysis of patient experience data in design inputs, risk management documentation and clinical evaluation reports, so as to establish a credible basis for subsequent regulatory interactions. Overall, companies should treat patient experience evidence as an indispensable component of U.S. market access and ongoing compliance.

FAQ

Does an update to a public FDA page necessarily represent a regulatory change?

No. An update to a public FDA page does not by itself constitute a regulatory change; companies must distinguish between news items, guidance documents, database pages, recall information and formal regulatory documents, and should verify any material point against the original FDA publication and the applicable regulations before taking action.

What should companies do after seeing an FDA update?

Companies should first determine whether the update affects product classification, the registration pathway, technical documentation or post-market obligations, and then decide whether project plans, dossiers or monitoring activities need to be updated. Recording the original link, publication date, scope of applicability and internal conclusion in the project file is recommended.

Content Review and Scope

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Program Team

Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope and limitations: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal opinions.

Related Reading

• WHO publishes report on a meeting on optimizing pediatric medicines for sickle cell disease — July 31, 2026
• Health Canada consults on changes to the list of recognized medical device standards — July 9, 2026
• FDA issues early alert on Baxter intravascular administration sets — July 14, 2026
• FDA seeks comments on certain non-device software functions

Need to Assess Your Registration Pathway?

Provide your product name, intended use, target countries and the documentation you already have, and AIMEILI can help determine the registration pathway, documentation gaps and compliance risks. Contact AIMEILI for further support.